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ABSTRACT 
Toxic insult from the heavy metal cadmium is known to induce the expression of 
metallothioneins (MT) which are cysteine-rich heavy metal binding proteins six to seven 
kilodaltons in size.  Previous research demonstrates that over-expression of MT-3 occurs 
in the majority of breast cancers and is associated with poor patient outcome.  
Furthermore, MT-3 has been shown to inhibit the growth of breast cancer and prostate 
cancer cell lines.  Studies have shown that the MT-3 protein contains 7 additional amino 
acids that are not present in any other member of the MT gene family, a 6 amino acid C-
terminal sequence and a Thr in the N-terminal region.  The unique N-terminal sequence 
is responsible for the growth inhibitory activity of MT-3 in the neuronal system, while 
the function of C-terminal region remains unknown.  The unique N- and C-terminal 
domains of MT-3 may play alternative roles in the differentiation and growth of breast 
cancer cells. 
One goal of this study was to characterize the function of the N- and C-terminal 
domains of MT-3 in the MCF7 breast cancer cell line.  For this purpose six different 
constructs of MTs were prepared which were as follows: wild type (WT) MT-3, MT-3 N-
terminal site directed mutagenesis (MT-3 P7T P9T), MT-3 C-terminal deletion (MT-3 
E55_E60del), WT MT-1E, and MT-1E mutated to contain the N -terminal of MT-3 (MT-
1E N4_C5insTCPCP), or the C-terminal (MT-1E G52_A53insEAAEAE), or both the N- 
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and the C-terminal of MT-3 (MT-1E N4_C5insTCPCP and G52_A53insEAAEAE).  
Each of these constructs was transfected into MCF7 cells.  Both the growth rate and the
transepithelial resistance (TER) of each cell line were measured.  Growth rates were 
statistically significantly reduced in all cell lines except MCF7 parent, Blank Vector, and 
MT-1E.  Vectorial active transport was increased in WT MT-3 and mutants containing 
the C-terminal of MT-3 as indicated by the formation of domes and increased TER.  
Observations of confluent cell cultures of mutant cell lines were also performed to 
determine the doming phenotype.  Doming was observed in cell cultures possessing the 
C-terminal region of MT-3, and the WT MT-3 cell line.  The data obtained suggests that 
the N-terminal region of MT-3 is involved in growth inhibitory activity even in the 
absence of the C-terminal domain.  The C-terminal region is involved in vectorial active 
transport which is indicated by the formation of domes in cell culture.  Depending on cell 
culture conditions the N-terminal region of MT-3 may attenuate the C-terminal domain’s 
ability to confer the doming phenotype.   
Microarray analysis of the MCF7 mutants was also performed to determine 
alterations in gene expression.  Overlapping hierarchal clustering demonstrates that the 
N- and C-terminal mutants have unique expression relationships.  Genes that were 
differentially regulated on the microarray and were further validated included the GAGE 
family antigens.  Several GAGE antigens were investigated to examine differential 
expression between the N- and C-terminal of MT-3.  These included:  GAGE12H, 
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GAGE12G, GAGE4, GAGE5, GAGE6, GAGE2E-1, GAGE2E-2, GAGE2E-1E, and 
GAGE2C.  A significant repression of GAGE2C, GAGE2E-1, GAGE2E-2, GAGE5, 
GAGE6, and GAGE12H antigen expression was seen in MCF7 mutants NT-1E, WT MT-
3, and MT-3ΔCT.  Up regulation of GAG2C, GAGE2E-2, GAGE5, and GAGE12H 
antigens occurred in MCF7 mutants MT-1E and CT-1E.  The GAGE12G antigen 
demonstrated increased expression in only MCF7 mutant cell lines MT-1E, CT-1E, and 
MT-3ΔNT.  The GAGE6 antigen was the only antigen to show repression in the presence 
of the N-terminal of MT-3 and up regulation in the presence of the C-terminal of MT-3 
but not in the presence of MT-1E.   
In conclusion, this study further characterizes the unique properties of the N- and 
the C-terminal domain of MT-3 and the potential role that it may play in the 
differentiation of certain breast cancers.  Dendrogram clustering analysis suggests that the 
N-terminal and C-terminal domains of MT-3 differentially regulate gene expression in 
MCF7 cells.  Increased doming activity and increased doubling times of mutant cell lines 
containing the C-terminal is suggestive of a differentiated phenotype of the cell line.  
Differential regulation of GAGE antigens and E-cadherin in the presence of MT-3 could 
be indicative of MT-3’s role in the epithelial to mesenchymal transition of cancer cells.
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            CHAPTER I 
INTRODUCTION 
Overview 
This study focused on creating a model system to study the effects that MT-3 and 
its unique N- and C-terminal domains have on the growth and differentiation of breast 
cancer.  This laboratory has previously demonstrated the overexpression of MT-3 is 
correlated to a poor diagnostic outcome in breast cancer patients.  The creation of MCF7 
cell lines expressing the N-terminal, C-terminal, or both of MT-3 followed by the 
subsequent microarray analysis will yield insight into the role of MT-3 in the 
differentiation of breast cancer.  Subsequent investigation into differentially regulated 
genes may elucidate targets for breast cancer therapy.   
Breast Cancer 
There are roughly 232,670 females and 2,360 males diagnosed with breast cancer 
every year.  Approximately 40,000 females and 430 males die from breast cancer disease 
annually as well (Jemal et al. 2002).  For women in the United States breast cancer is the 
leading cause of mortality from cancer.  Over the course of a lifetime one in eight 
females will be diagnosed with breast cancer.  The BRCA1 and BRCA2 genes are linked 
to a high susceptibility of breast cancer but only occur in five percent of breast cancer
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patients (Schmid et al. 1993), while many breast cancers contain point mutations in exons 
five through eight of the P53 gene indicating the occurrence may be due to xenobiotic-
induced mutations (Biggs et al. 1993).  This leaves the mechanism of occurrence for the 
majority of breast cancers unknown.  Evidence suggests that various sources of excess 
estrogen correlate to eventual breast cancer development (Henderson et al. 1982).  
Obesity also increases the risk of breast cancer by 80% for every 10 kg of body weight 
added post menopause (de Waard and Baanders-van Halewijn 1974).  Diets high in fiber 
rich foods may also reduce breast cancer risk since fiber prevents the intestinal 
reabsorption of excreted estradiols (Cohen et al. 1991).  Additionally macro- and 
micronutrient balance appear to play a role in genomic regulation, and preliminary data 
suggest that specific nutrient rich foods have a protective epigenetic effect.  Identifying 
the influence of environmental toxicants, hormonal exposure, nutrition, and disease on 
epigenetics and changes in gene regulation may have potential for development of new 
therapeutic approaches for the prevention of breast cancer (Hill and Hodsdon 2014). 
There are three main types of breast cancer cases:  ductal carcinoma in situ, 
invasive ductal carcinoma, and lobular carcinoma in situ.  Growth of breast cancer is 
often dependent on the overexpression of the estrogen receptor (ER) with seven out of ten 
breast cancers being categorized as ER+.  Overexpression of the epidermal growth factor 
receptor (HER2) occurs in 30% of breast cancer cases and is associated with an 
aggressive phenotype (Ross-Innes et al. 2012).  Antiestrogens, such as tamoxifen citrate, 
inhibit the binding of estradiol to the ER receptor making them useful in the treatment of 
ER positive breast cancers (Rockhill et al. 1998).  Tamoxifen citrate negates the 
stimulatory effects of estradiol, decreases circulating IGF-1 levels, and holds the cell in 
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the G1 phase of the cell cycle (Bernstein et al. 1990).  Tamoxifen citrate therapy has been 
utilized as a standalone treatment, paired with chemotherapy, or used after chemotherapy 
treatment of breast cancer with long-term treatments of more than one year conferring a 
survival advantage to patients using the therapy (Henderson et al. 1983). 
The MCF7 cell line was isolated from a sixty nine year old Caucasian female, and 
is derived from a malignant adenocarcinoma in a pleural effusion (Soule et al. 1973).  
The MCF7 cell line is non-doming, ER+, lacks Her2/neu receptor overexpression, has a 
karyotype of sixty-six to eighty-seven chromosomes, has an observed doubling time of 
twenty-nine hours, and has no basal expression of MT-3 (Gurel et al. 2003).  Since the 
MCF7 cell line retains the characteristics of the mammary epithelium it is widely used for 
in vitro breast cancer studies (Lacroix and Leclercq 2004).  The MCF7 cell line is able to 
form tumors in athymic mice with estrogen supplementation (Pratt and Pollak 1993).  
Knowledge of the signal transduction and molecular biology of estrogen stemmed from 
research conducted with MCF7 cells and depended on the cell lines unique properties 
(Levenson and Jordan 1997).   
Metallothionein 
Metallothioneins are a group of intracellular proteins with a high binding affinity 
for metals.  They are cysteine-rich and are of low molecular weight (six to seven kDa), 
and are typically a single polypeptide chain of sixty to sixty-eight amino acids.  
Metallothioneins have a unique amino acid composition that consists of twenty conserved 
cysteine residues and contain no aromatic amines or histidine.  Metallothionein was 
initially characterized as a Cd2+ binding protein first isolated from equine kidney cortex 
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in 1957 by Margoshes and Vallee (Thirumoorthy et al. 2007).  Presently metallothioneins 
are classified into four subgroups, MT-1, MT-2, MT-3, and MT-4.  In humans the MT 
genes are located at chromosome 16q13 and have twelve functional (MT-1A, MT-1B, 
MT-1E, MT-1F, MT-1G, MT1H, MT-1L, MT-1M, MT-1X, MT-2A, MT-3,and MT-4) 
and four nonfunctional (MT-1C, MT-1D, MT1I, and MT1J) isoforms.  Both MT-1 and 
MT-2 isoforms are distributed in tissues throughout the human body, whereas MT-3 and 
respectively found in the nervous system and kidney, and stratified epithelia (Cherian, 
Jayasurya, Bay 2003). 
Metallothioneins are physiologically important for the role they play in the 
homeostasis of essential metals such as zinc and copper during growth and development 
(Cousins 1983).  They also provide protection against reactive oxygen species, alkylating 
agents, and act to attenuate heavy metal-induced toxicity (Cherian, Jayasurya, Bay 2003).  
Metal ions are bound in two distinct clusters, one near the N-terminal which binds three 
metal ions to nine cysteine residues, and the other near the C-terminal which binds four 
metal ions to eleven cysteine residues (Thirumoorthy et al. 2007) (Figure 1).  
Metallothioneins are therefore able to donate zinc or copper to metallo-enzymes and 
transcription factors.  The binding affinity for metal ions to MTs is Zn2+ < Cd2+ < Cu+ < 
Hg2+ < Ag+ = Bi3+.  The Zn2+ ion is readily displaced by toxic metal ions enabling MTs to 
attenuate the toxic effects of those ions (Miles et al. 2000).  Metallothioneins bind Zn2+ in 
the human body thus acting as a reservoir of the metal ion for later use.  These Zn2+ ions 
play a role in various biological processes including DNA synthesis, enzymatic catalysis, 
gene expression, and apoptosis.  Deregulation of zinc transporters occurs in breast cancer 
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and results in an altered level of Zn2+ and MTs in the plasma.  The role that Zn2+ and MTs 
may play in cancer pathogenesis is still unknown (Gumulec et al. 2011). 
The expression of metallothioneins is also associated with protection against 
DNA damage and apoptosis.  Metallothioneins may function as transcriptional co-factors 
by donating zinc, and during cell proliferation and differentiation metallothioneins can 
translocate from the cytoplasm to the nucleus (Cherian, Jayasurya, Bay 2003).  Increased 
expression of metallothioneins has been observed in human liver, lung, kidney, colon, 
ovary, prostrate, nasopharynx, testes, salivary gland, thyroid, bladder, and breast tumors.  
There is a down regulation of metallothionein expression in hepatocellular carcinoma and 
liver adenocarcinoma (Cherian, Jayasurya, Bay 2003).   
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Figure 1:  Diagram depicting the binding of metal ions in the α and β domain of 
metallothionein by thiolate clusters with a representative MT amino acid sequence.  
Metal ions are represented by red spheres and sulfur atoms are represented by yellow 
spheres.  The β-domain is able to bind three metal ions, while the α-domain is able to 
bind four metal ions.  Adapted from (Ruttkay-Nedecky et al. 2013). 
 Metallothionein gene expression can be induced by the presence of cytokines, 
metals, and hormones (Bremner 1991).  Glucocorticoid, antioxidant, cyclic AMP, 
interferon, and TPA-responsive elements are present in the promoter region of 
metallothionein genes (Samson and Gedamu 1998).  The presence of heavy metals 
increases metallothionein expression through multiple metal response elements (MREs) 
present in the promoter regions of all metallothionein genes (Karin et al. 1984).  
Transcription factors found to bind MREs and induce gene expression include the zinc 
activated protein, MTF-1, zinc regulation factor, and metal response element binding 
factor (Czupryn, Brown, Vallee 1992).      
   7 
 
 The zinc sulfur interaction in metallothioneins provides a chemical basis where 
the cysteine group can act as a ligand and carry out oxidoreductive reactions (Maret 
2004).  Cysteinyl thiolate groups scavenge free hydroxyl and superoxide radical in a 
quenching process that involves all twenty cysteine residues, and occurs at a reaction rate 
340 fold higher than the rate for GSH (Thornalley and Vasak 1985).  Under normal 
conditions metallothioneins are concentrated in the cytoplasm, however, after treatment 
of cells with hydrogen peroxide, MT-1 MT-2 are rapidly translocated to the nucleus 
indicating that they may play a role as a nuclear antioxidant (Takahashi, Ogra, Suzuki 
2005). 
 
Figure 2:  Metallothionein gene regulation and function.  The metallothionein 
promoter contains several response elements that regulate transcription.  These include 
MRE, GRE, ARE, and STAT elements.  Adopted from (Ruttkay-Nedecky et al. 2013). 
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Metallothionein-3 
This isoform was first identified as a growth inhibitory protein in a study 
conducted by Uchida.  It was discovered that the survival rate of rat neonatal cortical 
neurons cultured with protein extracts from brains with Alzheimer’s disease (AD) 
increased in comparison to those supplemented with normal brain extract (Uchida et al. 
1991).  The increase in neurotrophic activity and survival of the cortical neurons in the 
AD brain was due to the absence of this growth inhibitory protein, which decreases 
neurotrophic conditions under normal circumstances (Uchida et al. 1991).  Further 
studies characterizing the molecule eventually revealed that the inhibitory molecule 
retained all the classic characteristics of a metallothionein, prompting it to be 
redesignated as MT-3 (Tsuji et al. 1992).  The growth inhibitory activity is unique to MT-
3 as none of the other isoforms are associated with this phenomenon (Ding, Ni, Huang 
2010).  Metallothionein-3 may also play an important role in lysosome function. In the 
absence of MT-3 there is a reduction of lysosomal enzymes, and decreased autophagic 
flux in astrocytes (Lee and Koh 2010). 
Even though MT-3 conserves approximately 70% of the amino acid sequence 
found in other MT isoforms, it is structurally unique in comparison to the other isoforms.  
The carboxy-terminal region (C-terminal domain) contains a unique acidic hexapeptide 
stretch EAAEAE, while an additional threonine residue is present in the amino-terminal 
region (N-terminal domain).  Those additional seven amino acids are not found in any of 
the other MT isoforms (Uchida et al. 1991).  The growth inhibitory activity of MT-3 is 
abolished by a double mutation in the N-terminal region resulting in the conversion of the 
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conserved TCPCP sequence to either TCSCA or TCSCT.  This implicates the N-terminal 
region of MT-3 in the growth inhibitory activity of MT-3 (Sewell et al. 1995).  The 
discovery that MT-3 possessed this unique biological property spurred interest into 
researching potential biological activities of all the MT isoforms.  Transgenic mice 
expressing MT-3 ectopically, in the same expression domain of MT-1, died of pancreatic 
acinar cell necrosis at 2-3 months of age (Quaife et al. 1998).  Transgenic MT-3 knock 
out mice exhibited sensitivity to aggravated neuronal damage following a middle cerebral 
artery occlusion when compared to WT mice (Koumura et al. 2009).  Growth inhibitory 
activity of MT-3 outside the neuronal system was demonstrated by stable expression of 
MT-3 in kidney, PC-3 prostate cancer cells, MCF7, and T-47D cell lines; however 
growth inhibitory activity did not occur when MT-3 was expressed in Hs578T and MDA-
MB-231 cell lines (Dutta et al. 2002; Gurel et al. 2003). 
The EAAEAE insert in MT-3 forms part of the backbone of the molecule and 
unlike MT-1/2 is not restricted by the metal-thiolate cluster enabling MT-3 to have a 
more dynamic loop conformation (Ding, Ni, Huang 2010).  Deletion of the EAAEAE 
sequence leads to decreased bioactivity due to the α-cluster being able to constrict further 
and alter domain-domain interactions (Ding, Ni, Huang 2010).   
Expression of MT-3 was initially thought to be restricted to the central nervous 
system, but expression of MT-3 has been detected in the normal human kidney, renal 
carcinoma, bladder cancer, and prostatic adenocarcinoma (Albrecht et al. 2008; Cherian, 
Jayasurya, Bay 2003).  The overexpression of MT-3 in human breast cancer cases has 
been correlated to poor prognosis (Sens et al. 2001).  Unlike the MT-1/2 isoforms MT-3 
expression is not induced by metals; however it has been demonstrated that expression of 
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MT-3 mRNA can be induced transiently, under the control of metal regulatory elements, 
in the proximal tubule cells once they are exposed to cadmium (Garrett et al. 2002).  
Previous studies provide evidence that MT-3 has specific patterns of expression, 
induction, and regulation and that further research into the role of MT-3 in breast cancer 
will provide new insights into the function of this metallothionein isoform. 
Metallothionein-3 and Breast Cancer 
Metallothionein-3 is not expressed in normal breast epithelial cells, but is highly 
expressed in the majority of breast tumor samples (Sens et al. 2001).  The role that MT-3 
plays in the differentiation of breast cancer has yet to be fully described.  The MCF7 cell 
line has no basal expression of MT-3, and does not form domes in cell culture.  The 
formation of domes indicates a differentiated phenotype capable of vectorially active 
transport (Claude 1978).  Overexpression of MT-3 in MCF7 or Hs578T cells results in 
growth inhibition while the overexpression of MT-1E does not result in growth inhibition 
(Gurel et al. 2003b).  Overexpression of MT-3 in cancer cell lines also results in 
increased drug resistance (Dutta et al. 2002).   
  Excess MT-3 may produce an excess of metal-free MT (apoMT) and in so doing 
generate a zinc-deficient state.  The creation of a zinc-deficient state may result in the 
dysregulation of zinc finger transcription factors (Hainaut and Milner 1993; Oren and 
Prives 1996; Zeng, Vallee, Kagi 1991) causing cell growth, differentiation, and 
programmed cell death to be affected.  The zinc-deficient state may also induce a p53-
null state since apoMT has the potential to sequester zinc from p53 similarly to other zinc 
chelators (Garrett et al. 1999).  Overexpression of MT-3 in tumors may cause a zinc-
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limiting cellular environment that favors tumor progression despite the slowed cellular 
growth (Sens et al. 2001). 
The presence of cadmium in human breast cancers indicates that cadmium may 
play a role in progression and development of the cancer (Antila et al. 1996).  Cadmium 
may act as an environmental estrogen by binding to and activating the ER-α receptor 
(Garcia-Morales et al. 1994).  Zinc was unable to induce the same increase in growth that 
cadmium was (Garcia-Morales et al. 1994).  Since MT-3 expression is induced by the 
presence of cadmium, studying the effect of the presence of MT-3 may yield new insights 
into breast cancer biology.   
Metallothionein-3 and E-cadherin Expression in HK2 Cells 
Fibrosis in chronic renal disease is due to toxic insult from many sources.  Such 
sources include diabetes and hypertension, and recent evidence suggests that 
environmental exposure to the heavy metal nephrotoxin, cadmium, may also contribute to 
this process.  In renal fibrosis seen in chronic renal disease, nearly one third of the 
resident fibroblasts derive from the proximal tubule epithelium, and the process by which 
this occurs is termed the epithelial-to-mesenchymal transition (EMT).  To better 
understand EMT an in vitro model system has been developed that consists of the 
normal, immortalized human proximal tubule cell line, HK2.  The HK2 cell line lacks 
several attributes seen in mortal cultures of human proximal tubules cells such as the lack 
of cell junctions, vectorial active transport, and E-cadherin expression, characteristics 
which are also exhibited in mesenchymal cells.  Restoration of MT-3 expression in this 
cell line led to an establishment of cellular junctions, vectorial active transport, and a 
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cadherin expression profile that is consistent with an epithelial phenotype (Bathula et al. 
2008)(Figure 3).  Expression of E-cadherin is essential for this transition due to the role 
of E-cadherin in the establishment of adherens junctions, which is required for vectorial 
active transport.  Current studies suggest that the EMT process itself may be controlled 
by MT-3 mediated transcriptional regulation of the E-cadherin gene.  E-box elements in 
the E-cadherin promoter allow for repression of E-cadherin (Batlle et al. 2000).   
 
 
 
Figure 3:  Dome formation by vectorial active transport.  Dome formation occurs 
when a monolayer of epithelial cells differentiates to possess apical and basolateral 
surfaces (Lever Julia 1985).  E-cadherin expression is required, and loss of transport 
occurs during renal fibrosis.  Figure adapted from (Lever Julia 1985). 
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GAGE Antigens 
Cancer/testis (CT) antigens are a group of proteins normally expressed in human 
germline cells and are present in various tumor types.  Currently there are eighty nine CT 
antigens all of which are encoded on the X chromosome (Gjerstorff and Ditzel 2008).  
The GAGE antigens are a family of CT antigens consisting of at least sixteen different 
genes, which are further divided into three groups based on their unique properties and 
are located on chromosome X at p11.23 (De Backer et al. 1999).  GAGE-1 contains a C-
terminal sequence not found in any of the other seven members.  The remaining members 
have amino acid sequences that are 98% identical, but can be divided into two separate 
groups.  GAGE-2 and GAGE-8 do not contain a tyrosine residue that may be 
phosphorylated (Y9), while GAGE-3-7 and GAGE-1 do not possess the same tyrosine 
residue (Salomon et al. 2003).  The promoters of the GAGE antigen family have no 
TATA box, and have only one or two different base pairs in the first fourteen hundred 
base pairs (Gjerstorff and Ditzel 2008).  The lack of a TATA box site for initiation allows 
transcription to start from several different sites leading to transcripts of varying lengths 
(Cilensek et al. 2002). 
The exact biological function of the GAGE antigens has yet to be fully elucidated, 
but recent evidence suggests that they may direct cell proliferation, differentiation, and 
the survival of germ line cells (Simpson et al. 2005).  Antiapoptotic properties have also 
been attributed to GAGE antigens (Cilensek et al. 2002).  Expression of the GAGE 
antigens normally occurs in a subset of oocytes in the adult ovary (Gjerstorff et al. 2006), 
adult male germ cells, and for a few weeks in fetal Leydig and Sertoli cells during the 
third trimester (Gjerstorff et al. 2007).  GAGE gene transcripts are present in numerous 
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types of cancers including 26% of breast cancers (Gjerstorff et al. 2006).  
Immunohistochemical analysis reveals a lower level frequency of GAGE antigen 
presence and a high degree of tumor heterogeneity (Kobayashi et al. 2000).  The 
expression of GAGE antigens in stomach cancer, neuroblastoma, and esophageal 
carcinoma has been correlated with a poor prognosis and an aggressive tumor type 
(Cheung, Chi, Cheung 2000; Kong et al. 2004; Zambon et al. 2001).  Since most normal 
tissues do not express GAGE antigens and areas of normal expression are immune-
privileged sites this makes them potentially useful targets as diagnostic and prognostic 
indicators, and as potential targets for immunotherapy treatment (Gjerstorff and Ditzel 
2008). 
Matrix Metalloproteinases 
Matrix metalloproteinases (MMPs) are a family of zinc dependent extracellular 
proteases that can completely remodel the extracellular matrix (ECM) allowing MMPs to 
function in a variety of biologic processes (Yadav et al. 2014).  These biological 
processes include: cytokine modulation, angiogenesis, growth factor bioavailability, cell 
migration, cell proliferation, receptor shedding, invasion, metastasis, and apoptosis (Roy 
and Walsh 2014).  The epithelial to mesenchyme transition (EMT) is a multistage process 
in which alteration of the microenvironment and cell differentiation is required for 
metastasis to occur.  During carcinogenesis MMPs act as mediators of alterations 
observed in the microenvironment during both early and late stages of disease 
progression (Yadav et al. 2014).  In breast cancer MMPs are over expressed prior to 
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EMT, but treatment of cells with centchroman reversed EMT by downregulating the 
HER2/ERK1/2/MMP-9 pathway (Khan et al. 2015).  
Leucine-Rich Repeat-Containing Proteins 
Leucine rich repeat containing (LRRC) proteins are a family of proteins known to 
be involved in protein-protein interactions and contain multiple LRR motifs of twenty to 
thirty amino acids.  The protein LRRC49 is a member of this family of proteins and has 
been shown to have elevated expression levels in ER+ breast cancers compared to ER- 
breast cancers, however its role in the differentiation of breast cancer remains unknown 
(De Souza Santos et al. 2008). 
Neural Tissue-specific Epidermal Growth Factor-like Repeat Domain-containing 
Protein 
Neural tissue-specific epidermal growth factor-like repeat domain containing 
protein two (NELL2) was first discovered as a mammalian homolog to the chicken NEL 
protein. It has been found to be expressed in neurons.  NELL2 may play a role in 
neuronal development, postnatal neural activity, and in cancer cell survival.  
Overexpression of NELL2 occurs in Burkitt’s lymphoma and in neuroblastomas (Maeda 
et al. 2001).  Recent studies have revealed that the expression of NELL2 is regulated by 
the oncogene E2F1 (Kim et al. 2013).  The E2F1 oncogene is a key regulator of cell 
proliferation.   Overexpression of NELL2 also increases the invasive activity of MCF7 
and MDA-MB-231 cells (Kim et al. 2013).   
Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthetase 2 
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Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthetase 2 (PAPSS2) is an 
enzyme that acts as a sulfur donor and catalyzes the transfer of sulfur to other molecules 
in a process known as sulfation.  Estrogen is metabolized and inactivated in target tissues 
via sulfation effectively inactivating the molecule to elicit growth.  It has been 
demonstrated that overexpression of PAPSS2 in MCF7 slows cellular proliferation both 
in vivo and in vitro arresting cell cycle progression and inducing apoptosis (Xu et al. 
2012). 
Glycogen Phosphorylase 
The metabolic enzyme glycogen phosporylase (PYGL) plays a role in the 
metabolic reprogramming of cancer cells.  In the hypoxic environment of a growing 
tumor glycogen metabolism is upregulated (Favaro et al. 2012).  The degradation of 
glycogen by PYGL is necessary for the function of the pentose phosphate pathway and 
cells without sufficient levels of PYGL undergo senescence (Favaro et al. 2012).  
Inhibition of PYGL and the subsequent metabolic alterations induces senescence in 
glioblastomas making it a potential therapeutic target (Abbadi et al. 2014). 
Voltage-Gated Sodium Channels 
Voltage gated sodium channels (VGSCs) are normally expressed in cells of the 
nervous system, and are responsible for the rising phase of action potentials (Pablo and 
Pitt 2014).  Expression of VGSCs also occurs in various metastatic cells and in specific 
cancer cell lines including the prostate (Shan et al. 2014).  Expression of the α subunits of 
the sodium channels Nav1.6 and Nav1.7 were found to be six to twenty-seven times 
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higher in PC-3 and LNCaP cells than in cells of benign prostatic hyperplasia (Shan et al. 
2014).  The overexpression of these subunits could serve as both a therapeutic target and 
prognostic biomarker. 
Statement of Purpose 
This study is designed to further elucidate the role of MT-3 in the regulation of 
cell differentiation in breast cancer.  The study aims to elucidate the role that the unique 
N- and C-terminal domains of MT-3 may play in the differential expression of genes 
involved in the progression of breast cancer.  MT-3 has been shown to be overexpressed 
in poor prognosis breast cancers (Sens, et al 2001), and has been shown to inhibit the 
growth of breast cancer and prostate cancer cell lines stably expressing MT-3 (Gurel, et 
al 2003).  When compared to other MT isoforms MT-3 contains an additional Thr in the 
N-terminal region and an acidic hexapeptide sequence EAEAAE in the C-terminal 
domain not found in other members of the MT gene family.  It was determined that the 
non-doming MCF7 cell line would be used to study MT-3 and its role in breast cancer 
since MCF7 cells have no basal expression of MT-3.         
In order to characterize the function of the N- and C-terminal domains of MT-3 in 
the MCF7 breast cancer cell line six different constructs of MTs will be prepared  as 
follows: wild type (WT) MT-3, MT-3 N-terminal point mutation (MT-3 P7T P9T), MT-3 
C-terminal deletion (MT-3 E55_E60del), WT MT-1E, and MT-1E insert mutation to 
contain the N -terminal of MT-3 (MT-1E N4_C5insTCPCP), or the C-terminal (MT-1E 
G52_A53insEAAEAE), or both the N- and the C-terminal of MT-3 (MT-1E 
N4_C5insTCPCP and G52_A53insEAAEAE).  Each of these constructs will be 
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transfected into MCF7 cells and three cell lines with the highest expression levels as 
determined by real time PCR and dot blot determination of protein levels will be utilized 
for observations.  Cell cultures will be observed for the formation of domes, doubling 
times will be determined using the MTT method, and the transepithelial resistance (TER) 
of each cell line will be measured to determine if vectorially active transport is occurring. 
 Microarray analysis of the MCF7 mutants will also be performed to determine 
alterations in global gene expression.  The bioinformatics core at the University of North 
Dakota School of Medicine and Health Sciences will analyze the microarray results for 
differentially expressed genes in the MCF7 mutant cell lines.  Overlap hierarchal 
clustering will be utilized to demonstrate and visualize the expression relationship 
between the N- and C-terminal mutants.  Differentially expressed genes based on 
microarray analysis will be confirmed by real time PCR.  This study may provide 
evidence regarding MT-3’s role in the differentiation of breast cancer, and elucidate the 
role the N- and C-terminal domains of MT-3 play in differentiation.
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CHAPTER II 
MATERIALS AND METHODS 
 
Reagents 
 
TRI Reagent and bromo-chloropropane (BCP) Phase separation reagent were 
purchased from Molecular Research Center, Inc. (Cincinnati, OH)  1.5 M Tris-HCl, 
ammonium persulfate, TEMED, Laemmli sample buffer, 0.5 M Tris-HCl, SYBR green 
PCR kits, cDNA synthesis kits, and pre-cast PAGE-gels were purchased from BIO-RAD. 
(Hercules, CA)  Albumin standards and BCA protein assay reagents were purchased from 
Pierce (Rockford, IL).  Glutaraldehyde solution, isopropanol, methanol, ethanol, DMEM 
nutrient, and F12 nutrient were purchased from Sigma-Aldrich (St. Louis, MO).  Fetal 
calf serum, penicillin-streptomycin 10,000 U/mL, and trypsin–ethylenediaminetetraacetic 
acid (0.05%, 0.02%) were purchased from Gibco (Life Technologies, NY).  Hydrophilic 
Polytetrafluoroethylene trans-well inserts designed for 6-well cell culture dishes were 
obtained from Millipore (EMD Millipore, MA).  For the microarray analysis the 
HumanHT-12 v4 Expression BeadChip (Illumina, CA) was selected. 
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METHODS 
Cell Culture 
The MCF7, and Hs578-T cells were obtained from American Type Culture 
Collection (Rockville, MD), and grown in Dulbeco’s Modified Eagles Medium (DMEM) 
(which contains 1000 mg/L glucose and L-glutamine, supplemented with 100 units/mL 
penicillin, 100 µg/mL streptomycin, 0.25 amphotericin B, 0.205 µg/mL sodium 
deoxycholate, and 3.7 g/L sodium bicarbonate) supplemented with 5% (v/v) fetal calf 
serum, 5 mg/ml glucose and routinely passaged at a 1:4 ratio upon attaining confluence.  
HK2 and HK2-MT3 cells were cultured using a growth formulation consisting of a 1:1 
mixture of DMEM and Ham's F-12 (which contains L-glutamine 0.146 g/L, 
supplemented with 100 units/mL penicillin, 100 µg/mL streptomycin, 0.25 µg/mL 
amphotericin B, 0.205 µg/mL sodium deoxycholate, and 3.7 g/L sodium bicarbonate) 
growth medium supplemented with selenium (5 ng/ml), insulin (5 μg/ml), transferrin (5 
μg/ml), hydrocortisone (36 ng/ml), triiodothyronine (4 pg/ml), and epidermal growth 
factor (10 ng/ml).  MCF7 cells and Hs578-T cells were fed every 3 days.  HK2 and HK2-
MT3 cells were fed fresh growth medium every 3 days and 2 days respectively.  The cells 
were kept in various tissue culture vessels at a constant temperature of 37° C in a 5% CO2 
: 95% atmosphere.  Medium was always replaced with fresh medium 24 h prior to 
subculturing.  Upon obtaining confluency, cells were subcultured in the following 
manner:  culture medium was aspirated and the cells were rinsed twice with sterile PBS 
(37° C) then trypsin–ethylenediaminetetraacetic acid (0.05%, 0.02%) (Life Technologies, 
NY) was added to the vessel.  The cells were monitored until disassociation from the 
bottom of the culture vessel occurred.  The cell suspension was then transferred to a 
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conical tube containing fetal calf serum (Gibco, Mexico) using additional PBS to suspend 
and transfer the cells.  A cell pellet was obtained by a five min centrifugation at 2,000 
rpm followed by the removal of the supernatant.  Cell pellets were resuspended in an 
appropriate volume of medium, and then seeded in the desired culture vessel.  Culture 
vessels were then placed in the incubator and cells were evenly distributed by gentle 
shaking in horizontal and vertical directions. 
Electroporation 
Transfection of HK2 and HK2-MT3 cells was performed with Amaxa Cell Line 
Nucleofector Kit V (Amaxa, NJ) according to the manufacturer’s protocol. Cells were 
suspended in Nucleofector Solution to a final concentration of 3×106 cells/100 μl. The 
cells were transfected using 2 μg of the Luciferase reporter construct, and 0.2 µg of the 
Renilla reporter construct. (Promega, WI) In amaxa-certified cuvettes, the cells were 
nucleofected using the program T-020. The nucleofected cells were transferred to 2000 
μL of prewarmed medium in 6-well plates after adding 500 µL prewarmed medium 
directly to the cuvette, and incubated for 36 h. 
E-Cadherin Promoter Constructs 
Vector Construction 
Wild Type Promoter Region of E-cadherin 
CCCATAACCCACCTAGACCCTAGCAACTCCAGGCTAGAGGGTCACCGCGTCT
ATGCGAGGCCGGGTGGGCGGGCCGTCAGCTCCGCCCTGGGGAGGGGTCCGC
GCTGCTGATTGGCTGTGGCCGGCAGGTGAACCCTCAGCCAATCAGCGGTACG
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GGGGGCGGTGCCTCCGGGGCTCACCTGGCTGCAGCCACGCACCCCCTCTCAG
TGGCGTCGGAACTGCAAAGCACCTG 
E-cadherin Promoter with Mutated E-boxes 
CCCATAACCCACCTAGACCCTAGCAACTCCAGGCTAGAGGGTCACCGCGTCT
ATGCGAGGCCGGGTGGGCGGGCCGTCAGCTCCGCCCTGGGGAGGGGTCCGC
GCTGCTGATTGGCTGTGGCCGGAACCTAAACCCTCAGCCAATCAGCGGTACG
GGGGGCGGTGCCTCCGGGGCTAACCTAGCTGCAGCCACGCACCCCCTCTCAG
TGGCGTCGGAACTGCAAAGAACCTA  
Mutated E-box regions are in bold.  The WT E-boxes and mutated E-box regions are 
underlined and the transcription start site is a single underline A.  The above sequences 
were ligated into the multiple cloning region of the pGL4.10[luc2] vector (Promega, WI) 
by GenScript (Piscataway, NJ).  The desired promoter sequence, length, and mutation of 
the E-boxes are based on research previously conducted by Batlle (Batlle et al. 2000b).  
Sequence design for ligation was done utilizing Vector NTI® computer software (Life 
Technologies, NY).  
Luciferase Assay 
The HK2 and HK2-MT-3 cell lines were transfected with the promoter reporter 
constructs previously described.  Transfected cells were rinsed with prewarmed PBS 
once, before adding 500 µL of Promega’s supplied lysis buffer PLB.  Cells were gently 
rocked for fifteen minutes to allow for complete lysis.  A total of 20 µL of cell lysate was 
added to 100 µL of Luciferase assay reagent, and the intensity of luminescence was 
measured using the Biotek FLx800 plate reader.  The Luciferase reaction was then 
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quenched using 100 µL of Promega’s Stop and Glo buffer, and then the luminescence of 
the Renilla was measured.  Lysates were measured four separate times per 
electroporation reaction.  The use of the Renilla reporter under the thymidine kinase 
promoter was used to normalize for transfection efficiency.    
Stable Transfection of MCF7 Cells 
The WT MT-3, WT MT-1E, MT-3ΔNT (MT-3 P7T P9T), MT-3ΔCT (MT-3 
E55_E60del), and NT-1E (MT-1E N4_C5insTCPCP), CT-1E (MT-1E 
G52_A53insEAAEAE), and CT-NT-1E (MT-1E N4_C5insTCPCP and 
G52_A53insEAAEAE) were blunt end ligated into the 6.2/V5 Destination vector 
(Invitrogen, NY) were linearized using BspHI (New England Biolabs, MA) prior to 
transfection using Effectene reagent (Qiagen, CA) (Figure 4).  Sequence design for 
ligation was done utilizing Vector NTI® computer software (Life Technologies, NY).  
Generation of the mutant sequences and ligation the genes was conducted by GenScript 
(Piscataway, NJ) using the WT MT-3 gene sequence.  Plasmids were transformed using 
One Shot® TOP10/P3 E. coli cells (Life Technologies, NY) and purified using a Qiagen 
midi prep kit (Qiagen, CA).   
Transfected cells were allowed to reach confluency in one well of a 6-well plate 
and then subcultured at a 1:10 ratio into a 6-well plate.  Transfected cells were 
propagated using media containing 10 µg/mL blasticidin (Invitrogen, CA) and observed 
for the formation of small isolated colonies.  Twenty four colonies were selected for each 
construct by using cloning rings that held 200 µL in volume (Sigma Aldrich, MO) and 
were always exposed to media containing 10 µg/mL blasticidin (Invitrogen, CA).  
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Selected colonies were subcultured into one well of a 24-well plate.  Upon attaining 
confluency transfected cells were subcultured into one well of a 12-well plate for a 1:2 
split ratio.  Colonies of transfected cells were subcultured a final time into a 6-well plate 
prior to a portion of the cells being harvested for mRNA isolation.  Cell lines expressing 
1x105 copies of the mRNA per 10 ng RNA were selected using qRT-PCR.  Protein 
expression for each cell line was determined using the dot blot method, and the three cell 
lines expressing the highest amount of protein were selected for downstream applications.  
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Figure 4:  Visual representation of the gene constructs generated to further examine 
the role of the unique N- and C-terminal domains of MT-3.  Constructs of MTs were 
prepared which were as follows: wild type (WT) MT-3, MT-3 N-terminal mutation (MT-
3 P7T P9T), MT-3 C-terminal deletion (MT-3 E55_E60del), WT MT-1E, and MT-1E 
mutated to contain the N-terminal of MT-3 (MT-1E N4_C5insTCPCP), or the C-terminal 
(MT-1E G52_A53insEAAEAE), or both the N- and the C-terminal of MT-3 (MT-1E 
N4_C5insTCPCP and G52_A53insEAAEAE). 
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Transfection of MCF7 Cells Using Qiagen Effectene 
Cells were split 24 h prior to transfection and were allowed to achieve 40-60% 
confluency.  A 1:10 ratio of DNA to Effectene was utilized for the procedure.  Linearized 
DNA was diluted to .1 µg/µL in Tris-EDTA, and a total of 1 µg DNA was used per 
transfection.  Qiagen supplied all needed reagents the formulation of which is proprietary.  
Diluted DNA was combined with 90 µL of buffer EC and 4 µL of Enhancer.  The 
combination was mixed, spun down briefly, and incubated at room temperature for 2-5 
minutes.  A total of 10 µL Effectene was added to the mixture, incubated for 5-10 min at 
room temperature, and then combined with 400 µL media prior to being added to the 
cells.  Before the DNA and Effectene complex was added to the cells they were rinsed 
once with PBS and had fresh media added to the culture vessel. 
Doming Observations for MCF7 Cell Lines 
MCF7 parent and MCF7 mutant cell lines were seeded at a 1:3 ratio in triplicate 
into T-25 flasks without vented caps.  Cells were all fed on a standard schedule and flasks 
were observed for domes once the culture obtained confluency.  Dome formation 
observation began 6 days post seeding.  A dome is considered formed when a group of 
several cells appears out of focus in relation to the monolayer, and when some portion of 
the dome is in focus the rest of the monolayer will appear out of focus.  A field of view 
using a 10x objective has a surface area of 1,180,370.75 µm2.  Flasks were scanned and 
when doming was observed that field of view and all the domes in it were counted.  A 
dome was only allowed to be counted once in one field of view.  Doming cultures had 
twenty-one field of views observed per T-25 culture flask. 
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Measurement of Transepithelial Resistance 
MCF7 parent and MCF7 mutant cell lines were seeded at a 1:2 ratio in triplicate 
onto 30-mm-diameter cellulose ester membrane inserts (Millipore, MA) placed in six-
well trays.  Beginning on the third day post-seeding, TER was measured every day with 
the EVOM Epithelial Voltohmmeter with a STX2 electrode set according to the 
manufacturer’s instructions (World Precision Instruments, FL).  This instrument 
measures the resistance to an alternating current flow through the filter containing the 
monolayer of cells. The resistance of the bare filter containing medium was subtracted 
from that obtained from filters containing cell monolayers. Two sets of four readings 
were taken at four different locations on each filter.  
Determination of Doubling Times 
Forty microliters of 5 mg/mL 3-(4,5-Dimethylthiazol-2-yl)-2,5 
diphenyltetrazolium bromide (MTT) (Sigma Aldrich, MO) was added to the media of 
cells plated at a 1:100 ratio.  After 3.5 h the cells were washed once with PBS, and the 
formazan crystals were solubilized in acidic propanol.  Absorption at 570 nm was 
determined.  Increases of absorption during the logarithmic growth phase were used to 
calculate doubling times. 
Dot Blot and Protein Extraction Method Specific for Dot Blot 
Determination of MT-3 protein content per microgram of total protein was 
accomplished by immunoblotting.  Cells were rinsed twice with PBS, and harvested in a 
buffer containing 10 mM Tris pH 7.4 and 75 mM NaCl.  Lysis of the cells was 
accomplished by freezing the cells for 30 seconds in liquid nitrogen followed by rapidly 
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thawing the cells in 37°C water.  The freeze thaw process was repeated three times.  
Samples were then centrifuged at 15,000xg for 15 minutes at 4°C the supernatant was 
collected for further use.  Protease inhibitors and a final concentration of 1 mM DTT was 
added to each sample.  A total of 2 µg of protein lysate in PBS and 1.5% glutaraldehyde 
was transferred to the dot-blot apparatus.  The protein lysate was transferred onto a 
PVDF membrane by gravity flow.  Samples were rinsed twice with PBS after having 
entered the membrane.  The membrane was then stained for MT-3 using the following 
dot blotting protocol:  the membrane was blocked using 1% BSA in PBS, following 
which the membrane was incubated with the primary MT-3 antibody at a 1:100 dilution 
in 1% BSA in PBS.  After incubation with the primary antibody the membrane was 
washed a couple of times and then incubated with the secondary anti-mouse alkaline 
phosphatase-conjugated secondary antibody (Promega, WI) at a 1:500 dilution in .4% 
BSA in PBS.  The antigen-antibody complexes were visualized using the alkaline 
phosphatase KI III (Vectore, CA).  The membrane was washed three times for 15 minutes 
in PBS between every step. 
Cell Culture Harvest 
Confluent cell cultures were harvested in the following manner:  cell culture 
vessels were rinsed twice with 10 mL PBS, 1.5 mL of PBS was added and the cells were 
mechanically scraped from the vessel, the suspension was then added to a 1.5 mL 
microfuge tube and pelleted at 2,000 rpm for 5 min at 4°C, the supernatant was aspirated 
and the remaining pellet was stored at -80°C for later use.   
Preparation of RNA for Microarray Analysis 
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Qiagen RNeasy Mini Kit (Qiagen, CA) was used to prepare RNA samples for 
mincroarray analysis.  Media was aspirated off of confluent T-75 flasks (Corning, NY) 
and 3 mL of lysis buffer RLT containing 10 µL of 14.3M betamercaptoethanol per mL 
was added.  The QiaShredder column was used to homogenize 700 µL of the lysates.  An 
equal volume of 70% ethanol was added to the homogenized lysate, and 700 µL was 
added to the RNeasy mini column.  The column was centrifuged at 10,000 x g for 15 
seconds after which the eluate was discarded.  A total of 700 µL buffer RW1 was added 
to column, centrifuged for 15 seconds at 10,000 x g, and the eluate was discarded.  The 
RNeasy column was transferred to a new collection tube and the following step was done 
twice: 500 µL buffer RPE was added, centrifuged for 15 seconds at 10,000 x g, and the 
eluate was discarded.  To remove all traces of remaining reagents the column was 
centrifuged for 1 minute at 10,000 x g with nothing added.  Elution of the RNA was 
accomplished by adding 50 µL of RNase free water and allowing the column to 
equilibrate at room temperature prior to centrifugation for 1 minute at 10,000 x g. 
RNA Isolation Using TRI Reagent 
RNA isolation for purposes other than microarray analysis was performed using 
TRI reagent (Molecular Research Center Inc., OH).  Following the removal of the media 
an appropriate volume of TRI reagent was added to the cells.  Cells were incubated at 
room temperature for 10 minutes with gentle rocking to ensure complete lysis.  The cell 
lysates was then pipetted repeatedly to shear the DNA prior to its transfer to an RNase 
free microfuge tube.  A total of 100 µL BCP was added per 1 mL of TRI reagent and the 
samples were vortexed for a minimum of 30 seconds to ensure complete mixing.  
Samples were incubated at room temperature for a minimum of 5 minutes prior to being 
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centrifuged at 12,000 x g for 15 minutes at 4°C.  The upper aqueous phase was 
transferred to a new tube and 500 µL of isopropanol was added.  Precipitated RNA was 
pelleted by centrifugation at 12,000 x g at 4°C.  Supernatant was removed and the RNA 
was washed twice with 75% ethanol followed by a centrifugation step at 7,500 x g for 5 
minutes at 4°C.  The RNA pellet was air dried for 2 minutes and resuspended in 30 µL of 
RNase free water. 
Determination of DNA and RNA Concentrations 
The concentration of DNA- or RNA-containing samples was determined using a 
Nano Drop (Thermo Scientific, TN) spectrophotometer and supplied computer software.  
Extinction coefficients were selected depending on if the sample was DNA or RNA.  The 
software determined the concentration of the nucleic acid based on the absorbance at 260 
nm of a 1 µL sample loaded onto the pedestal.  The A260/280 ratio was also examined to 
determine the quality of the sample.   
Determination of Protein Concentration of Cell Lysates 
The protein concentration of sample lysates was determined using Bradford 
reagent (Bio-Rad, CA) or using the BCA assay (Pierce, IL).  To make the working 
solution 1 part BCA reagent B was combined with 50 parts BCA reagent A, 200 µL of 
the working reagent was combined with 5 µL of the protein sample and 20 µL of distilled 
water, and incubated at 37°C for 30 min.  A 1x working solution was made from 4.5x 
Bradford reagent and 180 µL of working reagent was combined with 15 µL distilled 
water and 5 µL of the protein sample.  Bovine serum albumin standards at concentrations 
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of 0, 0.1, 0.2, 0.4, 0.6, 1.2, .1.6, and 2 µg/µL were used to make the standard curve.  
Absorbance was measured at 570nm on a BioTek ELx800 (BioTek, VT). 
cDNA Synthesis 
Conversion of RNA to cDNA was accomplished using the iScript cDNA 
Synthesis Kit (Bio-Rad, CA).  Per 20 µL reaction 5 µL of 20 ng/µL RNA was mixed with 
4 µL 5x iScript reaction mix, 1 µL iScript reverse transcriptase, and 10 µL nuclease free 
water.  The reaction was incubated using a thermocycler for 5 min at 25°C, 30 min 42°C 
and 5 min at 85°C followed by storage at -20°C. 
Real-time PCR Analysis Protocol for Bio-Rad Assays 
Gene expression was assessed with real time RT-PCR utilizing gene-specific 
primers (Bio-Rad, CA).  Real-time PCR was performed utilizing the SYBR Green kit 
(Bio-Rad, CA) with 2 μl of cDNA, 1 μL primers in a total volume of 20 μl in CFX real-
time detection system (Bio-Rad, CA). Cycling conditions were 94 ºC denaturation, 60ºC 
annealing, and 72 ºC extension. Amplification was monitored by SYBR Green 
fluorescence and compared with that of a standard curve consisting of serial dilutions of 
the control cDNA (Blank Vector MCF7 cells).  Gene expression is expressed as fold 
change compared to the control.  
Microarray Analysis 
 RNA isolated from each MCF7 mutant cell line using RNeasy Mini Kit (Qiagen, 
CA) was sent to the University of Minnesota Genomics Center for microarray 
hybridization.  HumanHT-12 v4 Expression BeadChip (Illumina, CA) was utilized to 
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determine genome wide gene expression levels.  The Bioinformatics core facility at the 
University of North Dakota School of Health and Medicine Sciences analyzed the 
resulting data for differentially expressed genes.  Hierarchical clustering and principal 
components analysis were used to assess the similarity and variation across isolates. The 
fold change of each probe in each array from a transformed cell line was calculated over 
its average expression level in the parental MCF7 and MCF7 Blank Vector cell line. In 
order to test whether transformed isolates have a nonrandom set of overlapping probes, 
we derived a probability function for the random number of overlapping probes, and used 
simulation test to find the statistical significance of the observed number of overlapping 
probes. Differentially expressed probe sets (DEGs) were identified using empirical Bayes 
method (Smyth 2004) and the p-values were adjusted using false discovery rate 
(Strimmer 2008). The analyses were carried out using R programming language and SAS 
JMPH software. 
 
Transformation 
 Plasmids received from Genscript (Piscataway, NJ) were transformed and 
propagated using One Shot® TOP10/P3 E. coli cells (Life Technologies, NY) as follows.  
An aliquot of E. coli cells were thawed on ice prior to adding 1 µL of 1µg/µL plasmid 
DNA in TE at pH 8.0.  Cells were incubated on ice for thirty minutes and heat shocked in 
a water bath at 42°C for thirty seconds.  Cells were placed back on ice for two minutes, 
prior to the addition of 250 µL room temperature S.O.C. medium.  Tubes were capped 
and incubated with shaking at 37°C for sixty minutes.  Each transformation was plated 
onto LB agar plates containing 100 µg/mL ampicillin and incubated at 37°C for no less 
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than 12 hours.  Individual colonies were selected for propagation in LB media prior to 
plasmid isolation. 
Plasmid Isolation 
 The Qiagen Midi Prep Kit (Qiagen, CA) was utilized to isolate plasmid DNA for 
downstream applications.  An individual transformed colony was incubated in sterile LB 
media containing 10 g tryptone, 5 g yeast extract, 10 g NaCl, and 0.1 g ampicillin per 
liter at 37°C for 8-12 hours while shaking at 300 rpm.  Cells were pelleted by 
centrifugation at 6000 x g for 15 minutes at 4°C, and resuspended in buffer P1 containing 
RNase A.  Buffer P2 was added, mixed by inversion, and incubated at room temperature 
for five minutes.  Buffer P3 was chilled to 4°C, added, mixed by inversion, and incubated 
on ice for five minutes.  A QIAGEN-tip was equilibrated with buffer QBT prior to having 
the plasmid mixture applied.  The QIAGEN-tip was washed twice with buffer QC, and 
the DNA was eluted using buffer QF.  Precipitation of the DNA was accomplished by 
adding isopropanol, and centrifuging at 15,000 x g for thirty minutes at 4°C.  The DNA 
pellet was washed using 70% ethanol and centrifuged at 15,000 x g for 10 minutes at 4°C.  
Supernatant was aspirated and the pellet was air dried for 10 minutes prior to being 
dissolved in TE buffer and pH 8.0.
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CHAPTER III 
RESULTS 
Metallothionein-3 Mediated Control of E-cadherin Expression Through E-box 
Promoter Elements 
Previous research has indicated that E-cadherin expression is down-regulated by 
the binding of the transcription factors slug and snail to promoter elements called E-
boxes (Batlle et al. 2000).  Expression of MT-3 in HK2 cells restores vectorial active 
transport and is accompanied by an increase in the expression of E-cadherin (Bathula et 
al. 2008).  The relationship between the expression of MT-3 and E-cadherin was 
examined using a luciferase construct containing 205 base pairs upstream of the E-
cadherin gene start site and twenty-seven base pairs past and including the start site.  This 
region contains three E-box elements capable of interacting with the transcription factors 
slug and snail. Mutation of the E-boxes prevents transcriptional repression by slug or 
snail (Batlle et al. 2000).  A construct with all three E-boxes mutated to prevent binding 
and a WT version were both transfected into WT HK2 cells or HK2 cells stably 
expressing MT-3 (HK2-MT-3).  Thirty-six hours post-transfection, cells were assayed to 
determine the relative activity of each promoter based on the amount of Luciferase 
produced, and normalized for transfection efficiency by measuring the luminescence of 
Renilla expressed using the thymidine kinase promoter.
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  The presence of MT-3 significantly increased E-cadherin expression levels in the 
case of the WT E-cadherin promoter construct and the mutated E-boxes promoter 
construct (Figure 5).  Normalized luminescence was 66.13 +/- 2.53, 100.37 +/- 35.16, 
135.87 +/- 42.63, and 214.7 +/- 55.03 for the WT promoter, WT promoter with MT-3, 
Mutated E-box promoter, and Mutated E-box promoter with MT-3 respectively.  Data 
indicates a 47.65% increase in expression was observed in HK2 cells expressing MT-3 
versus WT HK2 cells when transfected with the WT E-cadherin promoter construct, 
while the mutated E-box promoter construct had an 81.71% increase in expression over 
the WT construct in WT HK2 cells, and a 116.32% increase in expression in HK2 MT-3 
cells.  In HK2 cells a statistically significant increase in expression occurred when the 
WT E-cadherin promoter is compared to the E-cadherin promoter with mutated E-boxes 
(Figure S1).  A statistically significant increase also occurs when comparing the 
expression increase of HK2 to HK2-MT-3 cells transfected with the WT E-cadherin 
promoter (Figure 5).  Additionally, a statistically significant increase in expression occurs 
in the HK2-MT-3 cell line when comparing the WT E-cadherin promoter to the E-
cadherin promoter containing mutated E-boxes (Figure S2).           
 In HK2 cells mutation of the E-boxes in the E-cadherin promoter leads to a 
significant increase in E-cadherin expression (Figure S1).  The presence of MT-3 
increases E-cadherin expression significantly for the WT E-cadherin promoter and the 
mutated E-boxes promoter (Figure S2).  Data suggest that E-cadherin expression is 
modulated by the presence of MT-3 regardless of the status of the E-box elements.   
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Figure 5:  Comparison of both WT and Mutant E-box E-cadherin promoter 
constructs in both HK2 and HK2-MT-3 cell lines.  Both constructs were transfected 
into HK2 and HK2-MT-3 cell lines and are represented on the X axis.  Data are 
expressed as a ratio of the Luciferase signal to the Renilla signal on the Y axis.  Error 
bars represent the standard error of the mean (SEM).  Statistical significance indicated by 
* P-value less than 0.05 as determined using the one-way ANOVA as the test where N=3 
biological replicates.  Each condition is statistically significantly different in comparison 
to all other conditions.  The HK2 cell line transfected with the WT E-cadherin promoter 
is utilized as the official control.
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Doming Characteristics of MCF7 Cells Expressing Both or Either of the N- and C-
Terminal Domains of MT-3 
 Earlier work in our laboratory indicated that the restoration of MT-3 expression in 
the HK2 cell line led to an establishment of cellular junctions, vectorial active transport, 
and a cadherin expression profile that is consistent with an epithelial phenotype (Bathula 
et al. 2008) (Figure 3).  One goal of this study was to observe if either the N- or C-
terminal domain of MT-3 is responsible for the doming phenotype and if one domain 
may attenuate the activity of the other.  No doming activity was observed for the 
following MCF7 cell lines:  parent, Blank Vector, MT-1E, NT-1E, MT3ΔCT, or NT-CT-
1E (Table 1).  The formation of domes in cell culture was observed in the following 
MCF7 cell lines:  WT MT-3, MT3ΔNT, and CT-1E (Table 1).  In doming MCF7 cell 
lines more domes per field of view were observed in cell lines possessing only the C-
terminal region of MT-3 (Figure 6).  Domes were observed per one field of view that was 
1.9 cm2 using a 10x objective lens and the cellSens® microscope imaging software 
(Olympus, MA).   A total of twenty one fields of view were observed for each doming 
cell line and the number of observed domes (Figure 7).  Overall an average of 51.89 +/- 
7.89, 57.22 +/- 5.46, and 56.44 +/- 1.602 domes were observed when adding all twenty-
one fields of view for WT MT-3, MT-3ΔNT, and CT-1E MCF7 mutant cell lines 
respectively (Table 1) (Figures 8-10).  Domes per field of view averaged 2.69 for the CT-
1E cell line, wild type MT-3 had an average of 2.47 domes per field of view, and MT-
3ΔNT averaged 2.72 domes per field of view (Table 1). 
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Figure 6:  Images of MCF7 cells and MCF7 mutant cell lines doming in culture.  
Domes are indicated by white arrows.  A:  MCF7 parent.  B:  MCF7 CT-1E.  C and D: 
MCF7 MT-3 cell line; C depicts a larger doming structure while D depicts several 
smaller domes.  E: MCF7 MT-3ΔNT.  F:  MCF7 MT-3ΔNT.  Image taken 10 days after 
cells were passaged and seeded at a 1:3 ratio.  Magnification of 100x
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Figure 7:  Domes observed per 21 fields of view in a T-25 cell culture flask.  MCF7 
WT MT-3 averaged 51.89 +/- 7.89 domes per flask, MT-3ΔNT averaged 57.22 +/- 5.46 
domes per T-25 cell culture flask, and CT-1E averaged 56.44 +/- 1.60 domes per flask.  
Domes were not observed in the MCF7 parent, MT-3ΔCT, NT-1E, and MT-1E cell lines.  
No significant difference was determined among doming cell lines using the one-way 
ANOVA test.  
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MCF7 Cell Line Domes Observed 
in Cell Culture 
Average Number of 
Domes Observed 
per Field of View 
Average Number 
of Domes 
Observed per 21 
Fields of View 
WT MT-3 Yes 2.47 51.89 
MT-3ΔNT Yes 2.72 57.22 
MT-3ΔCT No 0 0 
MT-1E No 0 0 
CT-1E Yes 2.69 56.44 
NT-1E No 0 0 
NT-CT-1E  No 0 0 
Parent No 0 0 
Blank Vector No 0 0 
 
Table 1:  Doming phenotype and domes observed for MCF7 mutant cell lines.  Table 
indicates if domes were observed for each MCF7 mutant cell line.  Average number of 
domes observed per field of view and per 21 fields of view for doming cell lines is also 
displayed.  
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Figure 8:  Image of the MCF7 CT-1E mutant cell line depicting dome formation.  
Domes appear as out of focus areas in relation to confluent cells still attached to the 
culture vessel, and are indicated by white arrows.  Image taken 10 days after cells were 
passaged and seeded at a 1:3 ratio.    Magnification of 100x.
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Figure 9:  Image of the MCF7 WT MT-3 mutant cell line depicting dome formation.  
Domes appear as out of focus areas in relation to confluent cells still attached to the 
culture vessel, and are indicated by white arrows.  Image taken 10 days after cells were 
passaged and seeded at a 1:3 ratio.  Magnification of 100x.
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Figure 10:  Image of the MCF7 MT-3ΔNT mutant cell line depicting dome 
formation.  Domes appear as out of focus areas in relation to confluent cells still attached 
to the culture vessel, and are indicated by white arrows.  Image taken 10 days after cells 
were passaged and seeded at a 1:3 ratio.    Magnification of 100x.
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Doubling Times of MCF7 Cells Expressing Both or Either the N- and C-terminal 
Domains of MT-3 
 Metallothionein-3 is not expressed in normal breast epithelial cells, but is highly 
expressed in the majority of breast tumor samples (Sens et al. 2001).  Expression of MT-
3 in MCF7 or Hs 578T cells results in growth inhibition (Gurel et al. 2003) and increased 
chemotherapy drug resistance in MCF7 cells (Dutta et al. 2002).  The role of MT-3 and 
its unique N- and C-terminal domains plays in the differentiation of breast cancer has yet 
to be fully described, and here we examine each domain’s individual effect on MCF7’s 
growth rate.  MCF7 parent cells have a standard doubling time of 29 h (ATCC, MCF7), 
however in our laboratory we found that the doubling time for the MCF7 cells was 32.45 
h.  MCF7 cells expressing the MT-1E and Blank Vector construct had observed doubling 
times of 35.76 +/- 4.74 h and 39.51 +/- 5.96 h respectively.  As a control group MCF7 
parent, MCF7 MT-1E, and MCF7 Blank Vector had no statistically significant change in 
observed doubling times.  MCF7 cell lines containing the following constructs WT MT-
3, MT-3ΔNT, MT-3ΔCT, CT-1E, NT-1E, and NT-CT-1E  had observed doubling times 
of 53.1 +/- 2.2, 57.31 +/- 3.83, 64.73 +/- 5.24, 55.28 +/- 11.25, 60.96 +/- 3.3, and 56.96 
+/- 5.8 h respectively.  All cell lines possessing the N-terminal region, C-terminal region, 
or both the N- and C-terminal regions of WT MT-3 had a doubling time that was 
observed to be significantly slower than the control cell lines parent MCF7, MT-1E, and 
Blank Vector (Figure 11).   
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Figure 11:  MCF7 mutant cell line doubling times.  All mutant cell lines had increased 
doubling times in comparison to MCF7 parent except the MT-1E, and MCF7 Blank 
Vector cell lines.  Statistical significance indicated by **, ***, or **** P-value less than 
0.01, 0.001, and 0.0001 respectively using the one-way ANOVA followed by Tukey’s 
posttest comparing all mutant cell lines to MCF7 Parent.  Error bars represent SD.  Three 
biological replicates were tested.
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Evidence of a differentiated phenotype for cell lines possessing the C-terminal of MT-3 
can be observed morphologically by the formation of domes in cell culture (Figures 6, 8, 
and 10) (Table 1), and by the increase in TER (Figure 12).   
Transepithelial Resistance of MCF7 Cells Expressing Both or Either the N- and C-
Terminal Domains of MT-3 
 The integrity and permeability of a cell monolayer can be measured using 
transepithelial resistance (TER).  Measuring TER is a well-established method to 
determine the presence of tight junctions along with ionic permeability (Stevenson 1988).  
Expression of MT-3 in HK2 cells resulted in an increase in TER, dome formation, and 
the expression of E-cadherin indicating the formation and maintenance of cell to cell 
junctions characteristic of an epithelial cell (Bathula et al. 2008).  Alterations in TER 
based on the N- or C-terminal of MT-3 were examined in MCF7 cells to determine if 
either domain or both contribute to the formation of a differentiated epithelial cell type. 
 The daily average TER on days five, six, and seven varied to a large degree 
amongst the MCF7 mutant cell lines (Table 2).  This indicates that dome formation and 
the tight junctions associated with the epithelial phenotype may form and re-form as the 
monolayer is formed in MCF7 cells.  The combined average TER on days five, six, and 
seven post-seeding were used to compare all MCF7 cell lines.  The MCF7 parent cell line 
had a TER of 17.57 +/- 4.35 Ω/Cm2 and WT MT-3 had the highest average TER of 48.72 
+/- 6.79 Ω/Cm2.  MCF7 cell lines MT-1E, Blank Vector, MT-3ΔNT, MT-3ΔCT, CT-1E, 
NT-1E, and NT-CT-1E  had TER averages from days five to seven post seeding of: 33.17 
+/- 1.47, 21.64 +/- 5.62, 47.58 +/- 5.55, 32.87 +/- 5.62, 30.09 +/- 4.35, 34.72 +/- 2.67, and 
51.19 +/- 7.75 Ω/Cm2 respectively (Table 2).  It was observed that TER over seven days 
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of measurements was typically higher for cells possessing the C-terminal domain of MT-
3 (Figure 12).  When compared to the MCF7 parent cell line WT MT-3, MT-3ΔNT, and 
NT-CT-1E mutant cell lines had a significant increase in TER.  The average TER from 
day 5 indicated no significant increase using the MCF7 parent cell line as the control ( 
Figure S3), in the case of day 6 the NT-CT-1E cell line had a significant increase in TER 
in comparison to the parent cell line (Figure S4).  On day 7 the WT MT-3, MT-3ΔNT, 
and NT-CT-1E had significantly increased TER measurements in comparison to the 
MCF7 parent cell line (Figure S5). 
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Figure 12:  Average TER from days 5, 6, and 7 post seeding on trans-well inserts.  
Each MCF7 mutant cell line is represented on the x axis, while the calculated TER is 
displayed on the y axis.  Increased TER is indicative of the formation of tight junctions, 
and is associated with the doming phenotype.  Statistical significance indicated by ** P-
value less than 0.01 using the one-way ANOVA test and Dunnet’s posttest for multiple 
comparisons using the MCF7 parent cell line as a control.  Error bars represent SD.  
Three biological replicates were tested. 
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MCF7 Cell 
Line 
Average TER 
Day 5 
(Ω/Cm2) 
Average TER 
Day 6 (Ω/Cm2) 
Average TER 
Day 7 (Ω/Cm2) 
Average 
TER Day 5, 
6, and 7 
(Ω/Cm2) 
WT MT-3 35.32 +/- 5.81 53.57 +/- 13.88 52.27 +/- 12.11 48.72 +/- 
6.79 
MT-3ΔNT 41.99 +/- 9.26 53.08 +/- 9.57 47.67 +/- 5.16 47.58 +/- 
5.55 
MT-3ΔCT 26.39 +/- 1.99 44.06 +/- 3.37 28.16 +/- 5.87 32.87 +/- 
5.62 
MT-1E 32.68 +/- 7.26 35.92 +/- 6.98 30.91 +/- 8.41 33.17 +/- 
1.47 
CT-1E 22.96 +/- 
11.94 
29.34 +/- 9.40 37.98 +/- 7.07 30.09 +/- 
4.35 
NT-1E 37.58 +/- 
10.23 
34.3 +/- 9.4 32.28 +/- 12.61 34.72 +/- 
2.67 
NT-CT-1E 37.91 +/- 
12.10 
64.76 +/- 5.95 50.91 +/- 14.26 51.19 +/- 
7.75 
Parent 18.80 +/- 1.46 22.27 +/- 4.63 8.96 +/- 1.92 17.57 +/- 
4.35 
Blank Vector 41.99 +/- 5.38 27.38 +/- 10.76 36.80 +/- 6.48 35.39 +/- 
5.62 
 
Table 2:  Average TER for MCF7 mutant cell lines for days 5, 6, and 7.  Table 
indicates the average TER for each MCF7 mutant cell line for days 5, 6, and 7 expressed 
as Ω/Cm2 and indicating the SEM.  The combined average TER of days 5, 6, and 7 is 
used to evaluate the relationship between TER and the presence or absence of the N- and 
C-terminal of MT-3.  Three biological replicates were tested. 
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Microarray Analysis of MCF7 Cells Expressing Both or Either the N- and C-terminal 
Domains of MT-3 
The function of WT MT-3 and its N- and C-terminal domains in the 
differentiation of breast cancer remains to be fully elucidated.  Microarray analysis and 
subsequent investigation into differentially expressed genes (DEGs) could indicate 
important cellular pathways that become altered based on the presence or absence of WT 
MT-3 and its unique N-and C-terminal domains.  All the MCF7 mutant cell lines, except 
NT-CT-1E, underwent microarray analysis in order to determine DEGs.  Overlap 
hierarchical clustering demonstrates that the N- and C-terminal domains have unique 
expression relationships based on clustering dendrogram (Figure 13).  Mutants 
possessing either the N- or C-terminal regions also grouped together on the clustering 
dendrogram suggesting a similar pattern of gene expression among cell lines containing 
the same terminal regions (Figure 13).  Differentially regulated genes from microarray 
analysis that were significantly altered compared to Blank Vector as a control include:  
NELL2, PAPSS2, PYGL, VGSC, and LRRC49.  The GAGE antigen family was also 
found to be differentially regulated on the microarray uniquely by the N- or C-terminal 
domains of MT-3. 
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Figure 13:  Cluster dendrogram of MCF7 mutant cell lines.  Clustering determined 
using the Overlap Hierarchal Clustering based on differentially expressed genes.  
Clustering demonstrates that cells possessing the N- or C-terminal took residence in 
different areas of the diagram.  The proximity of one cell line to another indicates the 
degree of difference in gene expression.  Closer cell lines being more similar and further 
being more different.
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Differential Expression Analysis of LRRC49, NELL2, PAPSS2, PYGL, VGSC, and 
MMP-1 in MCF7 Cells Expressing Both or Either the N- and C-terminal Domains of 
MT-3 
 Microarray analysis indicated that LRRC49 expression had a 4.46 fold increase in 
the MCF7 WT MT-3 cell line, a 4.35 fold increase in the MCF7 MT-3ΔNT cell line, a 
5.53 fold increase in the NT-1E cell line, and a 1.54 fold increase in the CT-1E cell line.  
Expression of the NELL2 gene in MCF7 MT-3ΔNT and CT-1E mutant cell lines was 
induced by 1.2 fold and 1.07 fold respectively.  In the MCF7 WT MT-3, MT-3ΔNT, and 
CT-1E cell lines PAPSS2 expression was increased 1.22, 1.55, and1.35 fold respectively.  
Repression of PYGL occurred in the MCF7 MT-3ΔNT and CT-1E mutant cells lines 
where expression was .98 and .83 of the control respectively.  The VGSC family member 
SCNN1A was upregulated 2.35 fold in the MCF7 NT-1E cell line.  The previously 
mentioned genes underwent validation using qualitative real time PCR and were 
normalized to beta actin.  Validation data indicated that none of the genes were 
significantly up or down-regulated in any of the MCF7 mutant cell lines.  Based on 
microarray data from the HK2 MT-3 cell line, MMP-1 was also investigated in all the 
MCF7 mutant cell lines.  Qualitative real time PCR demonstrated that MMP-1 was 
significantly up-regulated 5.33 fold in the MCF7 NT-CT-1E cell line (Figure 14) using 
MCF7 Blank Vector as the control.  
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Figure 14:  Fold change in expression of the MMP-1 in MCF7 mutant cell lines. Data 
suggests that the presence of MT-3 may increase the expression of MMP-1 as indicated 
by the significant increase in expression of MMP-1 in the MCF7 NT-CT-1E mutant cell 
lines when compared to the MCF7 Blank Vector and MT-1E cell lines.  Statistical 
significance indicated by ** P-value less than 0.01. Significance determined using one-
way ANOVA and Dunnet’s posttest.  Error bars represent SD.  Three biological 
replicates were tested.
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GAGE Family Antigens are Differentially Expressed Based on the Presence or Absence 
of the N- and C-terminal Domains of MT-3 
Recent evidence suggests that the GAGE family antigens may direct cell 
proliferation, differentiation, and the survival of germ line cells (Simpson et al. 2005).  
To determine if the N- or C-terminal of MT-3 can differentially regulate genes, the 
microarray was examined for genes up- or down-regulated by one terminal being present 
and the opposite effect happening for the other terminal.  The GAGE family antigens 
were found to be down-regulated by WT MT-3 and when the N-terminal-only mutants, 
NT-1E and MT-3ΔCT, were present (Figures 15-22).  For several GAGE family antigens 
when the C-terminal-only cell line CT-1E was present expression significantly increased 
(Figures 15-22) in comparison to the Blank Vector cell line.  The microarray analysis 
indicated that GAGE12H, GAGE12G, GAGE6, and GAGE12F were differentially 
regulated by the N- or C-terminal of MT-3.  Additional GAGE family antigens were also 
tested by real time PCR.  Genes that were validated include GAGE12H, GAGE12G, 
GAGE4, GAGE5, GAGE6, GAGE2C, GAGE2E-1, and GAGE2E-2.  Due to a suitable 
primer being unavailable GAGE12F was not validated. 
 Using the MCF7 Blank Vector as a control, the relative changes in expression 
were determined from the microarray for the GAGE antigen family.  The MCF7 WT 
MT-3 cell line had repression of GAGE12H, GAGE12G, and GAGE6 to 0.93, 0.82, and 
0.85 respectively.  In the MCF7 MT-3ΔNT GAGE12F was upregulated 1.45 fold.  The 
MCF7 MT-3ΔCT cell line had repression of GAGE12H, GAGE12G, GAGE4, GAGE5, 
GAGE6, and GAGE12F to 0.52, 0.41, 0.46, 0.47, 0.43, and 0.62 respectively.  
Repression was again seen the N-terminal containing MCF7 NT-1E cell line where 
GAGE12H, GAGE12G, GAGE4, and GAGE6 expression levels were 0.66, 0.58, 0.64, 
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and 0.63 respectively of control.  For the C-terminal containing MCF7 CT-1E cell line 
there was an increase in expression for GAGE12H, GAGE12G, GAGE5, and GAGE12F 
genes of 2.55, 2.78, 2.93, and 3.27 respectively of control.  The GAGE12F gene was the 
only GAGE family antigen appearing on the microarray for the MCF7 MT-1E cell line 
and was up-regulated 1.23 fold. 
 Validation of the GAGE family antigens using real time PCR confirmed a pattern 
of up regulation in the presence of the MCF7 CT-1E cell line for the majority tested.  The 
GAGE2C, GAGE5, and GAGE12H were all significantly down-regulated in MCF7 WT 
MT-3, MT-3ΔCT, and NT-1E cell lines.  Those same genes were all significantly 
upregulated in MCF7 MT-1E and CT-1E mutant cell lines (Figures 15, 16, and 19).  The 
N-terminal cell lines MCF7 MT-3ΔCT and NT-1E along with WT MT-3 had the 
GAGE2E-2, GAGE6, and GAGE2E-1 genes significantly down-regulated (Figures 15, 
16, and 18).  For the MCF7 mutant cell lines containing the C-terminal GAGE2E-1 was 
significantly up-regulated in the MT-3ΔNT cell line (Figure 16), as was GAGE12G 
(Figure 20) and GAGE2E-2 (Figure 17).  Validation indicated that GAGE4, GAGE12G, 
and GAGE2E-2 were all significantly upregulated in the MCF7 cell lines expressing MT-
1E and CT-1E (Figures 16, 18, and 21).  The GAGE6 antigen was also significantly up-
regulated in the MCF7 CT-1E mutant cell line (Figure 19).    
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Figure 15:  Expression of GAGE2C gene in various MT mutants in MCF7 cells.  
Fold change in expression of the GAGE2C antigen in MCF7 mutant cell lines using 
Blank Vector as the control.  Statistical significance indicated by **** P-value less than 
0.0001. Significance determined using one-way ANOVA and Tukey’s posttest.  Error 
bars represent SEM.  Three biological replicates were tested. 
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Figure 16:  Fold change in expression of the GAGE2E-1 antigen in MCF7 mutant 
cell lines.  Changes in fold expression were measured using MCF7 blank vector as the 
control.  Statistical significance indicated by ** or **** P-value less than .01, .0001 
respectively.  Significance determined using one-way ANOVA and Tukey’s posttest.  
Error bars represent SEM.  Three biological replicates were tested.
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Figure 17:  Fold change in expression of the GAGE2E-2 in MCF7 mutant cell lines.  
Changes in fold expression were measured using MCF7 blank vector as the control.  
Statistical significance indicated by *, ***, or **** P-value less than .05, .001, and .0001 
respectively.  Significance determined using one-way ANOVA and Tukey’s posttest.  
Error bars represent SEM.  Three biological replicates were tested.
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Figure 16:  Fold change in expression of the GAGE4 in MCF7 mutant cell lines.  
Changes in fold expression were measured using MCF7 blank vector as the control.  
Statistical significance indicated by ** or **** P-value less than .01, and .0001 
respectively.  Significance determined using one-way ANOVA and Tukey’s posttest.  
Error bars represent SEM.  Three biological replicates were tested.
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Figure 19:  Fold change in expression of the GAGE5 in MCF7 mutant cell lines.  
Changes in fold expression were measured using MCF7 blank vector as the control.  
Statistical significance indicated by **** P-value less than .0001.  Significance 
determined using one-way ANOVA and Tukey’s posttest.  Error bars represent SEM.  
Three biological replicates were tested.
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Figure 20:  Fold change in expression of the GAGE6 in MCF7 mutant cell lines.  
Changes in fold expression were measured using MCF7 blank vector as the control.   
Statistical significance indicated by ** or *** P-value less than .01, and .001 
respectively.  Significance determined using one-way ANOVA and Tukey’s posttest.  
Error bars represent SEM.  Three biological replicates were tested.
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Figure 21:  Fold change in expression of the GAGE12G in MCF7 mutant cell lines. 
Changes in fold expression were measured using MCF7 blank vector as the control.  
Statistical significance indicated by ** or **** P-value less than .01, and .0001 
respectively.  Significance determined using one-way ANOVA and Tukey’s posttest.  
Error bars represent SEM.  Three biological replicates were tested.
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Figure 22:  Fold change in expression of the GAGE12H in MCF7 mutant cell lines. 
Changes in fold expression were measured using MCF7 blank vector as the control.  
Statistical significance indicated by *, **, or **** P-value less than .05, .01, and .0001 
respectively.  Significance determined using one-way ANOVA and Tukey’s posttest.  
Error bars represent SEM.  Three biological replicates were tested.
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CHAPTER IV 
DISCUSSION 
The Role of MT-3 in Transcriptional Regulation of E-cadherin 
A hallmark of the transition between epithelial and mesenchymal cell types is in 
the inverse expression of E- and N-cadherin (Bathula et al. 2008).  Loss of E-cadherin 
expression is one of the events prior to a cell becoming mesenchymal, while induction of 
E-cadherin is needed for the formation of adherens junctions and a complete epithelial 
layer.  The HK2 cell line has no basal expression of MT-3 and is non-doming; however 
restoration of MT-3 expression increases E-cadherin expression and creates a doming 
phenotype (Bathula et al. 2008).  Transcriptional regulation of E-cadherin has also been 
shown be repressed by the E-box binding transcription repressors Slug and Snail (Batlle 
et al. 2000).  Transcription repressors Slug and Snail bind E-box elements CAGGTG, 
TCACCTG, and CACCTG and mutation of those sequences to AACCTA, AACCTA, 
and AACCTA prevents the binding and E-cadherin expression increases (Batlle et al. 
2000).  The role of MT-3 in the regulation of E-cadherin expression was examined using 
a WT E-cadherin promoter and one with four mutated E-boxes.  Expression of MT-3 in 
HK2 cell lines caused a significant increase in the expression of E-cadherin in the case of 
the WT promoter and the promoter containing mutated E-boxes (Figure 5).  The presence 
of MT-3 appears to have an additive effect increasing the expression of E-cadherin
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beyond the baseline expression for the construct containing the mutated E-boxes.  If MT-
3 functioned to regulate E-cadherin expression by interacting with E-box elements it 
would be expected that the expression would not increase once the E-box elements had 
been mutated.  Data suggest that 36 hours post-transfection MT-3 up-regulates E-
cadherin expression and this is not wholly mediated by E-box repression.  It is likely that 
MT-3 is indirectly up-regulating E-cadherin expression and not independently interacting 
with the promoter.   
The Role of MT-3 in MCF7 Cell Differentiation 
Studies have demonstrated that MT-3 is involved in the maintenance of vectorial 
active ion transport in human proximal tubule cells (Kim 2002), and that restoration of 
MT-3 expression in HK2 cells confers the doming phenotype (Bathula et al. 2008).  The 
doming phenotype indicates that cell cultures derived from transporting epithelial cells 
have retained vectorial active transport activity (Lever, 1985).  Domes appear in cell 
culture vessels as out of focus in relation to the monolayer indicating they are raised and 
detached from the cell culture vessel due to water following transported ions in the 
basolateral surface.  This study demonstrated that MCF7 cells differentiated into a 
doming phenotype when the C-terminal of MT-3 was present (Figures 6, 8, 9 and 10).  
Cell lines able to form domes had no significant difference in the visible doming activity 
when compared to other cell lines possessing the doming phenotype (Figure 7).  Utilizing 
TER measurements is an established method to determine the presence of tight junctions 
and ionic permeability of the cell monolayer (Kang et al. 2015).  Transepithelial 
resistance measurements were significantly higher in the MCF7 mutant cell lines WT 
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MT-3, MT-3ΔNT, and NT-CT-1E when compared to the parent MCF7 cell and the MT-
1E cell line (Figure 12).  The findings indicate that the C-terminal of MT-3 may be 
responsible for the formation of tight junctions and conferring the doming phenotype, but 
that the C-terminal alone may not lead to significant increase in TER as indicated by the 
MCF7 mutant cell line CT-1E (Figure 12). 
The N-terminal of MT-3 contains a Thr residue that is not present in any of the 
other MT isoforms (Andrews 2000; Aschner et al. 1997; Kagi and Hunziker 1989).  It has 
been demonstrated that this Thr is responsible for the growth inhibitory activity 
associated with MT-3 (Kagi and Hunziker 1989).  Addition of MT-3 to cultured rat 
cortical neurons inhibits survival and neurite outgrowth, and elevating the expression of 
MT-3 in rat C-6 glial cells also confers growth inhibitory activity (Tsuji et al. 1992).  
This growth inhibitory activity is unique to MT-3 and despite a 63-69% sequence identity 
no other MT isoforms confer growth inhibition (Aschner et al. 1997).  The growth 
inhibitory activity of MT-3 also occurs in MCF7 and Hs578T cells, but not to the MDA-
MB-231 and T-47D cell lines (Gurel et al. 2003c).  This study examined the doubling 
time of MCF7 cells expressing WT MT-3, MT-1E, and mutant forms containing either 
the N-terminal or C-terminal domains of MT-3 and both the N- and C-terminal of MT-3 
(Figure 3).  The MCF7 WT MT-3, MT-3ΔNT, MT-3ΔCT, CT-1E, and NT-1E cell lines 
had a significant increase in doubling time in comparison to the parent MCF7 cell line 
and Blank Vector (Figure 11).  The MCF7 MT-1E cell line did not have a significant 
change in doubling time when compared to the parent MCF7 and Blank Vector cell lines.  
The growth inhibition of cell lines containing the C-terminal of MT-3 but not the N-
terminal may be due the C-terminal domain initiating differentiation of the cell line into a 
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more epithelial phenotype as indicated by dome formation in cell culture (Figures 6-10) 
and increased TER (Figure 12).  
Overexpression of MT-3 occurs in breast cancers and esophageal cancers (Somji 
et al. 2010; Tian et al. 2013) that have a poor prognosis.  The presence of MT-3 may 
serve as a protective mechanism inhibiting cellular proliferation by altering the 
expression of other genes (Tian et al. 2013).  Microarray analysis and overlap 
hierarchical clustering implicated that there were unique alterations in gene expression 
based on the presence or absence of the N- or C-terminal of MT-3 (Figure 13).  Further 
investigation of up or down-regulated genes based on the microarray included: PAPSS2, 
MMP-1, LRRC49, NELL2, PYGL, VGSCs, and the family of GAGE antigens.  The 
protein LRRC49 has been shown to have elevated expression levels in ER+ breast 
cancers compared to ER- breast cancers (De Souza Santos et al. 2008), and NELL2 is 
over expressed in Burkitt’s lymphoma and in neuroblastomas (Maeda et al. 2001).  
Overexpression of PAPSS2 in MCF7 cells has been shown to slow cellular proliferation 
by arresting cell cycle progression and inducing apoptosis (Xu et al. 2012), while down 
regulation of PYGL can cause cancer cells to undergo senescence (Favaro et al. 2012).  
Expression of the VGSCs Nav1.6 and Nav 1.7 occurs in prostate cancer cell lines and 
other metastatic cells (Shan et al. 2014).  Although significant alterations in expression of 
NELL2, PAPSS2, PYGL, VGSCs, and LRRC49 was indicated by microarray analysis 
real time PCR indicated there was no significant changes in expression for those genes in 
comparison to MCF7 Blank Vector as a control.  During carcinogenesis MMPs act as 
mediators of alterations observed in the microenvironment during both early and late 
stages of disease progression (Yadav et al. 2014).  The MCF7 mutant cell line NT-CT-1E 
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had a significant increase in the expression of MMP-1 using MCF7 Blank Vector as a 
control (Figure 14).  An over-expression of MT-3 and subsequent increased expression of 
MMP-1 may be indicative of disease progression. 
The N-and C-terminal of MT-3 Differentially Regulate the Expression of GAGE 
Antigens 
The exact biological function of the GAGE antigens remains unknown recent 
evidence suggests that they may direct cell proliferation, differentiation, and the survival 
of germ line cells (Simpson et al. 2005), additionally antiapoptotic properties have also 
been attributed to GAGE antigens (Cilensek et al. 2002).  The presence of GAGE 
antigens in various aggressive carcinomas makes any alteration in expression of interest 
(Cheung, Chi, Cheung 2000; Kong et al. 2004; Zambon et al. 2001).  Microarray analysis 
indicated that the expression of GAGE antigens in MCF7 mutant cell lines was down-
regulated when the N-terminal of MT-3 was present and up-regulated when the C-
terminal alone was present.  Real time PCR on several family members of the GAGE 
antigens supported that finding (Figures 15-22). 
Data suggests that the presence of the N-terminal of MT-3 may repress the 
expression of GAGE2C and GAGE2E-1 as indicated by the significant reduction in 
expression of GAGE2C and GAGE2E-1 in WT MT-3, MT-3ΔCT, and NT-1E MCF7 cell 
lines (Figures 15-16).   Lack of the N-terminal restores expression of GAGE2E-1 to 
control levels with the exception of the MT-3ΔNT mutant cell line which exhibits 
repression in comparison to the blank vector cell line (Figure 16).  Real time PCR 
suggests that the presence of the N-terminal of MT-3 may repress the expression of 
GAGE2E-2 since there is significant reduction in expression of GAGE2E-2 in WT MT-3, 
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MT-3ΔCT, and NT-1E (Figure 17).  The presence of any MT lacking the N-terminal of 
MT-3 may induce the expression of GAGE2E-2 as indicated by the MT-1E, MT-3ΔNT, 
and CT-1E mutant cell lines which exhibit increased expression in comparison to the 
Blank Vector cell line (Figure 17).  The C-terminal of MT-3 may induce the expression 
of GAGE4 and GAGE5 as indicated by the significant increase in expression of GAGE4, 
GAGE 5, and GAGE12H in the MCF7 CT-1E cell line (Figures 18, 19, 22).  
Metallothioneins may also induce GAGE4, GAGE5, and GAGE12H antigen expression 
as indicated by the increase seen in the MT-1E cell line (Figures 18, 19, 22).  The 
presence of the N-terminal of MT-3 may repress the expression of GAGE5 as indicated 
by the significant reduction in expression of GAGE5 in WT MT-3, MT-3ΔCT, and NT-
1E MCF7 cell lines (Figure 19).  Data suggests that the presence of the C-terminal of 
MT-3 may induce the expression of GAGE6 as indicated by the significant increase in 
expression of GAGE6 in CT-1E cell line.  The N-terminal of MT-3 may be responsible 
for repressing the expression of GAGE6 since WT MT-3, MT-3ΔCT, and NT-1E all have 
decreased levels of GAGE6 mRNA (Figure 20).  Expression of GAGE12G had a 
significant increase in expression in MT-1E, MT-3ΔNT, and CT-1E MCF7 mutant cell 
lines (Figure 21).  The N-terminal of MT-3 may be responsible for repressing the 
expression of GAGE12H since WT MT-3, MT-3ΔCT, and NT-1E all have suppressed 
levels of GAGE12H mRNA in those cell lines (Figure 22).     
Wild type MT-3 consistently down-regulated GAGE antigen expression despite 
having both the N- and C-terminals present suggesting that the N-terminal of MT-3 was 
actively altering gene expression in the MCF7 cell line.  The GAGE antigens were often 
up-regulated in the MCF7 CT-1E mutant cell line as was the MCF7 MT-1E cell line.  
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This may indicate the metallothioneins may differentially up regulate GAGE antigen 
expression, while the N-terminal of MT-3 is able to down regulate expression of those 
same antigens. 
Increased expression of E-cadherin is indicative of an epithelial phenotype while 
the over-expression of N-cadherin coupled with down-regulation of E-cadherin indicates 
a transition to a more mesenchymal state.  Data indicates that in the HK2 cell line 
expression of MT-3 re-establishes the expression of E-cadherin and subsequently the 
cells differentiate into an epithelial phenotype.  Data from this study suggests that MT-3 
up regulates E-cadherin expression independent of E-box elements and most likely 
indirectly from E-cadherin promoter itself.  No alteration in the expression of E-cadherin 
and N-cadherin occurred in the MCF7 mutant cell lines as indicated by RT-PCR (data not 
shown).  However, the MCF7 cell line is known to maintain an epithelial phenotype.   
The downstream effects of MT-3 expression in the progression and differentiation 
of breast cancer are many, and could be dependent on which region, the N- or C-terminal, 
is active.  The antiapoptotic properties of GAGE antigens along with their potential 
involvement in cell proliferation, survival of germline cells and differentiation correlates 
to a role in cancer that allows the tumors to divide and survive.  Data suggests that the N-
terminal region if active may be able to reduce the expression of GAGE antigens, while 
the presence of MTs may actually increase the presence of several GAGE antigens.  
Overall the role that MT-3 and MTs play in the regulation of GAGE antigens needs to be 
further evaluated.  Since the GAGE antigens are normally expressed in immune 
privileged tissues their overexpression in tumors allows them to be targeted by 
immunotherapy treatments.  These tumors though are highly heterogenic in terms of 
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which GAGE antigens are present.  It appears as though MTs may only upregulate a 
subset of the family.  Researchers may use the presence or absence of MTs to help pick 
which GAGE antigens would be most beneficial to target during immunotherapy.
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APPENDICES 
APPENDIX A 
Abbreviations 
°C Degree Centigrade 
BSA Bovine Serum Albumin 
Cd2+ Cadmium 
cDNA Copy of DNA made from mRNA 
Da Dalton’s 
DMEM Dulbecco’s Modified Eagles’ Media 
DNA Deoxyribonucleic Acid 
ECM Extracellular Matrix 
EMT Epithelial-to-Mesenchymal Transition 
ER Estrogen Receptor 
MT Metallothionein
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MT-1E Metallothionein-1E 
MT-3 Metallothionein-3 
mRNA Messenger RNA 
MRE Metal Response Element 
µM Micromolar 
µL Microliter 
µg Microgram 
mL Milliliter 
mM Millimolar 
ng Nanogram 
PCR Polymerase Chain Reaction 
RNA Ribonucleic Acid 
RT-PCR Reverse Transcriptase Polymerase Chain Reaction 
Thr Threonine 
TE Tris-EDTA 
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TER Transepithelial Resistance 
RNA Ribonucleic Acid 
SD Standard Deviation 
SEM Standard Error of the Mean 
WT Wild Type 
Zn2+ Zinc 
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APPENDIX B 
Supplemental Figures 
 
 
Supplemental Figure 23:  Relative Expression of E-cadherin WT promoter for HK2 
and HK2-MT-3 cells.  The WT E-cadherin promoter construct was transfected into HK2 
and HK2-MT-3 cell lines that are represented on the x axis.  Data are expressed as a ratio 
of the Luciferase signal to the Renilla signal on the y axis. Statistical significance 
indicated by * P-value less than .05 as determined using the one-way ANOVA.   Error 
bars represent SEM.  Three biological replicates were tested.   
  
* 
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Supplemental Figure 24:  Relative Expression of E-cadherin Mutant E-boxes 
promoter for HK2 and HK2-MT-3 cells.  The E-cadherin promoter construct with 
mutated E-boxes was transfected into HK2 and HK2-MT-3 cell lines that are represented 
on the x axis.  Data are expressed as a ratio of the Luciferase signal to the Renilla signal 
on the y axis. Statistical significance indicated by * P-value less than .05 as determined 
using the one-way ANOVA.  Error bars represent SEM.  Three biological replicates were 
tested. 
  
* 
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Supplemental Figure 25:  Average TER from Day 5 post seeding on trans-well 
inserts.  Each MCF7 mutant cell line is represented on the x axis, while the calculated 
TER is displayed on the y axis.  Increased TER is indicative of the formation of tight 
junctions, and is associated with the doming phenotype.  Error bars represent SD.  Three 
biological replicates were tested.   
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Supplemental Figure 26:  Average TER from day 6 post seeding on trans-well 
inserts.  Each MCF7 mutant cell line is represented on the x axis, while the calculated 
TER is displayed on the y axis.  Increased TER is indicative of the formation of tight 
junctions, and is associated with the doming phenotype.  Statistical significance indicated 
by * P-value less than .05 using the one-way ANOVA test and Dunnet’s posttest for 
multiple comparisons using the MCF7 parent cell line as a control.  Error bars represent 
SD.  Three biological replicates were tested. 
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Supplemental Figure 27:  Average TER from day 7 post seeding on trans-well 
inserts.  Each MCF7 mutant cell line is represented on the x axis, while the calculated 
TER is displayed on the y axis.  Increased TER is indicative of the formation of tight 
junctions, and is associated with the doming phenotype.  Statistical significance indicated 
by * P-value less than .05 using the one-way ANOVA test and Dunnet’s posttest for 
multiple comparisons using the MCF7 parent cell line as a control.  Error bars represent 
SD.  Three biological replicates were tested.
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